This press release may contain certain “forward-looking statements.” All statements, in the absence of historical facts, are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “intentions,” “believe,” “wait,” “expected,” “wants” or similar expressions, and include known and unknown risks and uncertainties. While the Company believes that the expectations reflected in these forward-looking statements are appropriate, they involve assumptions, risks and uncertainties, and these expectations may prove to be false. Risks and uncertainties include the possibility that the transaction will not occur as expected if events leading to the termination of the merger agreement occur, where the expected merger financing is not available for any reason, or if one or more of the various transaction conditions of the merger are not met or waived, as well as other risks and uncertainties regarding the merger agreement and concentration that are discussed in the 13E-3 list to be submitted to the SEC. A number of factors could cause actual results to differ materially from those contained in a forward-looking statement. Investors should not place undue reliance on these forward-looking statements, which are made only at the time of this press release. Contrary to securities legislation, the entity undertakes no commitment to update these forward-looking statements. PEKIN, 19 years old. November 2020 /PRNewswire/ — China Biologic Products Holdings, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), the first fully integrated biopharmaceutical plasma company in China, announced today that it has entered into a final agreement and proposed merger (the “merger agreement”) with CBPO Holdings Limited (parent company) and CBPO Group Limited (Sub). Under the merger agreement and subject to conditions, Merger Sub will merge with and with the company, with the remaining company as a surviving entity and becoming a wholly owned subsidiary of the parent company (the “merger”) in a transaction involving a capital value of approximately $4.76 billion. View original content:www.prnewswire.com/news-releases/china-biologic-enters-into-merger-agreement-for-going-private-transaction-301177142.html Simultané for the implementation of the merger agreement, Beachhead, Double Double, Point Forward, 2019B Cayman, Parfield, Hillhouse, V-Sciences, M. Joseph Chow, Biomedical Treasure, Biomedical Future, Biomedical Development, some members of the company`s management (such as management members, rollover management members) (all previous individuals, together the “Rollover Securityholders”), TB MGMT, TB Executives and TB Innovation have entered into a parent voting and support agreement, under which Rollover security holders have agreed to choose all shares that are advantageous to them in favour of approval and the merger contract.
and to participate in the parent company, immediately before or at the time of effective time, certain shares (the rollover shares) and the company`s share premiums that are in the advantage of rollover security holders.